CN1216872C - 喹唑啉衍生物及其药物用途 - Google Patents
喹唑啉衍生物及其药物用途 Download PDFInfo
- Publication number
- CN1216872C CN1216872C CN998111910A CN99811191A CN1216872C CN 1216872 C CN1216872 C CN 1216872C CN 998111910 A CN998111910 A CN 998111910A CN 99811191 A CN99811191 A CN 99811191A CN 1216872 C CN1216872 C CN 1216872C
- Authority
- CN
- China
- Prior art keywords
- amino
- optional
- carboxyl
- carboxyl substituted
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
实施例序号 | IC50值(μM) | t1/2(分钟) |
128101213161718 | 0.360.140.0350.170.440.30.840.140.14 | 781752916724997>240260103 |
21222427293234 | 0.340.30.324.01.71.50.36 | -10479263>24074709 |
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23563398 | 1998-08-21 | ||
JP235633/1998 | 1998-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1319096A CN1319096A (zh) | 2001-10-24 |
CN1216872C true CN1216872C (zh) | 2005-08-31 |
Family
ID=16988920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN998111910A Expired - Fee Related CN1216872C (zh) | 1998-08-21 | 1999-08-20 | 喹唑啉衍生物及其药物用途 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6867214B1 (zh) |
EP (1) | EP1114035B1 (zh) |
JP (1) | JP2002523404A (zh) |
KR (1) | KR20010089168A (zh) |
CN (1) | CN1216872C (zh) |
AT (1) | ATE326451T1 (zh) |
AU (1) | AU772771B2 (zh) |
CA (1) | CA2341357A1 (zh) |
DE (1) | DE69931378T2 (zh) |
ES (1) | ES2259476T3 (zh) |
HU (1) | HUP0103387A3 (zh) |
WO (1) | WO2000010982A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2358314A1 (en) * | 1999-11-01 | 2001-05-10 | Suntory Limited | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor |
CA2365606A1 (en) * | 2000-02-22 | 2001-08-30 | Suntory Limited | Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient |
HUP0201282A3 (en) * | 2000-02-22 | 2003-02-28 | Daiichi Asubio Pharma Co Ltd | Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient |
US6500835B2 (en) | 2000-02-22 | 2002-12-31 | Suntory Limited | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
ATE478857T1 (de) * | 2000-09-18 | 2010-09-15 | Toa Eiyo Ltd | N-substituierte benzothiophensulfonamid-derivate |
US20070105908A1 (en) * | 2003-06-27 | 2007-05-10 | Dainippon Sumitomo Pharma Co., Ltd. | Thiazolimine compound and oxazolimine compound |
US7423155B2 (en) | 2003-11-14 | 2008-09-09 | 3M Innovative Properties Company | N-sulfonyldicarboximide containing tethering compounds |
US7544756B2 (en) | 2005-09-30 | 2009-06-09 | 3M Innovative Properties Company | Crosslinked polymers with amine binding groups |
MX2008015196A (es) | 2006-05-31 | 2008-12-15 | Asubio Pharma Co Ltd | Compuesto de anillo de 7 miembros, proceso para producir el mismo, y su uso medico. |
US9371307B2 (en) | 2011-09-12 | 2016-06-21 | The Johns Hopkins University | Serine protease inhibitors |
WO2018215818A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE913473A1 (en) | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
JP2982454B2 (ja) | 1991-12-20 | 1999-11-22 | 王子製紙株式会社 | 感熱記録体 |
US5691335A (en) * | 1994-07-29 | 1997-11-25 | Suntory Limited | Imidazolidine derivative and use thereof |
US5814631A (en) * | 1995-09-28 | 1998-09-29 | Suntory Limited | Quinazoline derivatives and applications thereof |
EP0906273B1 (en) * | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
-
1999
- 1999-08-20 ES ES99938565T patent/ES2259476T3/es not_active Expired - Lifetime
- 1999-08-20 JP JP2000566256A patent/JP2002523404A/ja active Pending
- 1999-08-20 US US09/763,213 patent/US6867214B1/en not_active Expired - Fee Related
- 1999-08-20 KR KR1020017002168A patent/KR20010089168A/ko not_active Application Discontinuation
- 1999-08-20 EP EP99938565A patent/EP1114035B1/en not_active Expired - Lifetime
- 1999-08-20 WO PCT/JP1999/004503 patent/WO2000010982A1/en not_active Application Discontinuation
- 1999-08-20 CA CA002341357A patent/CA2341357A1/en not_active Abandoned
- 1999-08-20 AT AT99938565T patent/ATE326451T1/de not_active IP Right Cessation
- 1999-08-20 DE DE69931378T patent/DE69931378T2/de not_active Expired - Lifetime
- 1999-08-20 HU HU0103387A patent/HUP0103387A3/hu unknown
- 1999-08-20 AU AU53037/99A patent/AU772771B2/en not_active Ceased
- 1999-08-20 CN CN998111910A patent/CN1216872C/zh not_active Expired - Fee Related
-
2005
- 2005-03-08 US US11/073,654 patent/US7169951B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20010089168A (ko) | 2001-09-29 |
EP1114035B1 (en) | 2006-05-17 |
HUP0103387A2 (hu) | 2002-04-29 |
DE69931378T2 (de) | 2006-11-02 |
CA2341357A1 (en) | 2000-03-02 |
EP1114035A1 (en) | 2001-07-11 |
WO2000010982A1 (en) | 2000-03-02 |
US20050148608A1 (en) | 2005-07-07 |
ES2259476T3 (es) | 2006-10-01 |
ATE326451T1 (de) | 2006-06-15 |
AU5303799A (en) | 2000-03-14 |
CN1319096A (zh) | 2001-10-24 |
US7169951B2 (en) | 2007-01-30 |
JP2002523404A (ja) | 2002-07-30 |
US6867214B1 (en) | 2005-03-15 |
HUP0103387A3 (en) | 2002-07-29 |
AU772771B2 (en) | 2004-05-06 |
DE69931378D1 (de) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1129597C (zh) | 杂环化合物和以其为有效成分的抗肿瘤剂 | |
CN1216872C (zh) | 喹唑啉衍生物及其药物用途 | |
CN1116288C (zh) | 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物 | |
CN1281590C (zh) | 具有抑制血管生成活性的六员氨基酰胺类衍生物 | |
CN1659145A (zh) | 作为egf-r和her2激酶抑制剂的3-氰基喹啉 | |
CN1324360A (zh) | 双环氮杂环 | |
CN1444563A (zh) | 喹啉和喹唑啉衍生物 | |
CN1633431A (zh) | 喹唑啉衍生物类激酶抑制剂 | |
CN1185737A (zh) | 异噻唑酮类化合物 | |
CN1966506A (zh) | 吡唑并嘧啶酮衍生物及其制备方法和用途 | |
CN1886134A (zh) | 有效的抗糖尿病化合物的盐和多晶型物 | |
CN1366461A (zh) | 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物 | |
CN1658872A (zh) | 抗过敏药 | |
CN1218472A (zh) | 药学上有用的化合物 | |
CN1608065A (zh) | 苯基取代的三唑及其作为选择性alk5激酶抑制剂的用途 | |
CN1720237A (zh) | 3h-喹唑啉-4-酮衍生物 | |
CN1303384A (zh) | 吡咯并[1,2-a]吡嗪sPLA2抑制剂 | |
CN1125575A (zh) | 粘附受体拮抗剂 | |
CN1074904A (zh) | 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物 | |
CN1245978C (zh) | 含有胃促胰酶抑制剂作为活性成分的预防和治疗各种与嗜酸性粒细胞增多有关的疾病的药物 | |
CN101054380A (zh) | 用作细胞周期依赖性蛋白激酶抑制剂的吡唑并嘧啶类衍生物 | |
CN1166623C (zh) | 2-苯氧基苯胺类衍生物 | |
CN1245979C (zh) | 含有胃促胰酶抑制剂作为有效成分的预防和治疗皮炎的药物 | |
CN1525956A (zh) | α-氨基-N-羟基-乙酰胺衍生物 | |
CN1849306A (zh) | 基质金属蛋白酶抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUNTORY LTD Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20030418 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030418 Address after: Tokyo, Japan Applicant after: Daiichi Suntory Pharma Co., Ltd. Address before: Osaka Applicant before: Suntory Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: SUNTORY LTD |
|
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Patentee after: Daiichi Asubio Pharma Co., Ltd. Address before: Tokyo, Japan Patentee before: Daiichi Suntory Pharma Co., Ltd. |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |